Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439602 | 1.00 | TRPV4 (0.43) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL56634 | 0.82 | TRPV4 (0.57) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL3639193 | 0.79 | CYP11B1 (0.34) | CYP11B1CYP11B2MAOBMAOAAR | |
| SCHEMBL1395661 | 0.78 | MAOB (0.61) | CYP11B1CYP11B2MAOBMAOASLC1A5 | |
| SCHEMBL30475151 | 0.78 | MAOB (0.61) | CYP11B1CYP11B2MAOBMAOASLC1A5 | |
| SCHEMBL3636063 | 0.78 | PTGES (0.33) | CYP11B1CYP11B2AR | |
| SCHEMBL26623457 | 0.78 | CYP2A6 (0.42) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL5958536 | 0.77 | PYCR1 (0.39) | ESR1ESR2DGAT1 | |
| SCHEMBL16961441 | 0.77 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL2890266 | 0.77 | CNR2 (0.50) | CYP11B1CYP11B2GRM4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957040-B | Dibromo column [5] aromatic compound and preparation method thereof, conjugated polymer thereof and preparation method and application of polymer | 武汉工程大学 | 2023-08-25 | — | — | CN | claimed |
| CN-110078668-B | Phenyl imidazole XOR inhibitor, preparation and application | 华南理工大学 | 2023-03-24 | — | — | CN | claimed |
| CN-114957040-A | Dibromo column [5] arene compound, preparation method thereof, conjugated polymer thereof, preparation method and application of polymer | 武汉工程大学 | 2022-08-30 | — | — | CN | claimed |
| CN-103936622-B | 5-bromo-2-fluorobenzonitrile synthesis method | Qidong dongyue pharmaceutical co ltd | 2015-07-15 | — | — | CN | claimed |
| CN-102190797-A | Quick synthesizing method of triazinyl covalent bond organic framework material with nano pores and application thereof | UNIV ANHUI | 2011-09-21 | — | — | CN | claimed |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12543496-B2 | Organic molecules for optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2026-02-03 | — | — | US | disclosed |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | TRPV4 510/4885CYP11B1 1916/4885CYP11B2 1572/4885 |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | TRPV4 516/4885CYP11B1 2062/4885CYP11B2 1692/4885 |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | TRPV4 3530/4885CYP11B1 2670/4885CYP11B2 2011/4885 |
| US-12543496-B2 | Organic molecules for optoelectronic devices | OR10J3, SCO2, ORC3 | TRPV4 1356/4885CYP11B1 1118/4885CYP11B2 722/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | TRPV4 1449/4885CYP11B1 796/4885CYP11B2 629/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | TRPV4 2218/4885CYP11B1 1827/4885CYP11B2 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.